Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Net Cash Flow (2021 - 2025)

InMed Pharmaceuticals' Net Cash Flow history spans 5 years, with the latest figure at -$2.4 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 9.83% year-over-year to -$2.4 million; the TTM value through Dec 2025 reached $3.5 million, up 157.81%, while the annual FY2025 figure was $4.5 million, 292.42% up from the prior year.
  • Net Cash Flow reached -$2.4 million in Q4 2025 per INM's latest filing, down from -$1.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $8.0 million in Q3 2021 to a low of -$5.4 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$252946.8, with a median of -$1.4 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: crashed 348.26% in 2023, then skyrocketed 721.59% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$4.1 million in 2021, then surged by 164.03% to $2.6 million in 2022, then crashed by 171.02% to -$1.8 million in 2023, then dropped by 17.07% to -$2.2 million in 2024, then dropped by 9.83% to -$2.4 million in 2025.
  • Per Business Quant, the three most recent readings for INM's Net Cash Flow are -$2.4 million (Q4 2025), -$1.7 million (Q3 2025), and $6.4 million (Q2 2025).